SP-102

Scilex Holding Company presented post-hoc analysis of the C.L.E.A.R. trial demonstrating clinically meaningful safety and efficacy of SP-102 (SEMDEXA™) for lumbosacral radicular pain at the ASIPP Annual Meeting.

Scilex Holding Company has received FDA orphan drug designation for colchicine in treating pericarditis, potentially providing seven years of market exclusivity upon approval.

Scilex Holding Company has submitted a Supplemental New Drug Application (SNDA) to the FDA for ELYXYB in acute pain management.

Scilex Bio's KDS2010, a reversible MAO-B inhibitor, is in Phase 2 trials for obesity, with U.S. patient enrollment planned for 2025, targeting metabolism without affecting appetite.

Scilex Pharmaceuticals gains FDA agreement on NDA path for SP-103, a triple-strength lidocaine topical system, after a successful Phase II meeting.